Search results for "Doxorubicin"

showing 10 items of 298 documents

Viral Bcl2s' transmembrane domain interact with host Bcl2 proteins to control cellular apoptosis

2020

© The Author(s) 2020.

0301 basic medicineProgrammed cell deathScienceProtein domainGeneral Physics and AstronomyApoptosisBiologyVirus-host interactionsArticleGeneral Biochemistry Genetics and Molecular BiologyFluorescenceCell Line03 medical and health sciences0302 clinical medicineProtein Domainsimmune system diseaseshemic and lymphatic diseasesmedicineHumansAmino Acid SequenceAuthor CorrectionPeptide sequenceneoplasmsMultidisciplinaryVirus–host interactionsQCell MembraneGeneral ChemistryViral proteinsmedicine.diseaseControl cellLymphomaCell biologyVirusTransmembrane domain030104 developmental biologyProto-Oncogene Proteins c-bcl-2Cell cultureApoptosisDoxorubicin030220 oncology & carcinogenesisbiological phenomena cell phenomena and immunityProtein MultimerizationHydrophobic and Hydrophilic InteractionsProteïnesProtein Binding
researchProduct

Essential Oils, Pituranthos chloranthus and Teucrium ramosissimum, Chemosensitize Resistant Human Uterine Sarcoma MES-SA/Dx5 Cells to Doxorubicin by …

2021

The multidrug resistance phenotype is a global phenomenon and causes chemotherapy failure in various cancers, such as in uterine sarcomas that have a high mortality rate. To overcome this phenotype, there is growing research interest in developing new treatment strategies. In this study, we highlight the potential of two essential oils from the Apiaceae family, Pituranthos chloranthus (PC) and Teucrium ramosissimum Desf. (TR), to act as chemopreventive and chemosensitizing agents against two uterine sarcoma cell lines, MES-SA and P-gp-overexpressing MES-SA/Dx5 cells. We found that PC and TR were able to inhibit the cell viability of sensitive MES-SA and resistant MES-SA/Dx5 cells by a sligh…

0301 basic medicineProgrammed cell deathuterine sarcomaP-glycoproteindoxorubicin03 medical and health sciences0302 clinical medicinemedicineDoxorubicinTX341-641Viability assayessential oilsP-glycoproteinNutrition and DieteticsbiologyChemistryNutrition. Foods and food supplyCell cyclechemosensitization030104 developmental biologyApoptosisCell culture030220 oncology & carcinogenesisCancer researchbiology.proteinIntracellularFood Sciencemedicine.drugNutrients
researchProduct

Selective targeting of collagen IV in the cancer cell microenvironment reduces tumor burden

2018

Goodpasture antigen-binding protein (GPBP) is an exportable1 Ser/Thr kinase that induces collagen IV expansion and has been associated with chemoresistance following epithelial-to-mesenchymal transition (EMT). Here we demonstrate that cancer EMT phenotypes secrete GPBP (mesenchymal GPBP) which displays a predominant multimeric oligomerization and directs the formation of previously unrecognized mesh collagen IV networks (mesenchymal collagen IV). Yeast two-hybrid (YTH) system was used to identify a 260SHCIE264 motif critical for multimeric GPBP assembly which then facilitated design of a series of potential peptidomimetics. The compound 3-[4''-methoxy-3,2'-dimethyl-(1,1';4',1'')terphenyl-2'…

0301 basic medicineTumor microenvironmentChemistryKinaseMesenchymal stem cellEMTPhenotype03 medical and health sciences030104 developmental biologyOncologyGPBPPrecursor cellCancer cellCancer researchmedicinecollagen IVtumor microenvironmentDoxorubicinSecretiondrug-resistant cancermedicine.drugResearch PaperOncotarget
researchProduct

Effect of Buthionine Sulfoximine on the Sensitivity to Doxorubicin of Parent and MDR Tumor Cell Lines

1994

We have studied the interaction of glutathione-depleting concentrations of buthionine sulfoximine (BSO) with the anti-proliferative activity of doxorubicin (DXR) in three tumor lines, the mouse B16 melanoma. Friend erythroleukemia and the human K562 leukemia, both as DXR-sensitive and-resistant (with typical multidrug resistance) variants. BSO significantly enhanced the DXR effects in the wild-type Friend and K562 leukemias, and especially in the drug-resistant subline of Friend leukemia. BSO did not modify DXR accumulation and retention in the latter clone. Moreover, neither BSO nor verapamil used alone completely reversed the resistance to DXR of this cell line; their combination was more…

0301 basic medicineVincristineFriend leukemia030106 microbiologyPharmacologyMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMethionine Sulfoximinehemic and lymphatic diseasesTumor Cells CulturedmedicineAnimalsHumansPharmacology (medical)DoxorubicinButhionine sulfoximineButhionine SulfoximinePharmacologyChemistryDrug SynergismGlutathionemedicine.diseaseGlutathioneDrug Resistance MultipleMultiple drug resistanceLeukemiaInfectious DiseasesOncologyDoxorubicinVincristine030220 oncology & carcinogenesismedicine.drugK562 cellsJournal of Chemotherapy
researchProduct

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: Predictive value of DNA-PK and phosphorylated ACC

2016

// Francesco Perrone 1,* , Gustavo Baldassarre 2,* , Stefano Indraccolo 3,* , Simona Signoriello 4 , Gennaro Chiappetta 1 , Franca Esposito 5 , Gabriella Ferrandina 6 , Renato Franco 1,15 , Delia Mezzanzanica 7 , Maura Sonego 2 , Elisabetta Zulato 3 , Gian F. Zannoni 6 , Vincenzo Canzonieri 2 , Giovanni Scambia 6 , Roberto Sorio 2 , Antonella Savarese 8 , Enrico Breda 9 , Paolo Scollo 10 , Antonella Ferro 11 , Stefano Tamberi 12 , Antonio Febbraro 13 , Donato Natale 14 , Massimo Di Maio 1,16 , Daniela Califano 1 , Giosue  Scognamiglio 1 , Domenica Lorusso 7 , Silvana Canevari 7 , Simona Losito 1 , Ciro Gallo 4,** and Sandro Pignata 1,** 1 Istituto Nazionale per lo Studio e la Cura dei Tumor…

0301 basic medicinemedicine.medical_specialtyLiposomal Doxorubicinovarian cancer; phase 3 clinical trial; predictive factors; pACC; DNA-PKDNA-Activated Protein KinaseDisease-Free Survivalpredictive factorDNA-PK03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOvarian cancerPhase 3 clinical trialAntineoplastic Combined Chemotherapy ProtocolsOverall survivalMedicineHumansDNA-PK; ovarian cancer; pACC; phase 3 clinical trial; predictive factorsGynecologyOvarian NeoplasmsAdvanced ovarian cancerphase 3 clinical trialbusiness.industrySignificant differenceDNA-PK; Ovarian cancer; PACC; Phase 3 clinical trial; Predictive factors; Antineoplastic Combined Chemotherapy Protocols; DNA-Activated Protein Kinase; Disease-Free Survival; Female; Humans; Ovarian Neoplasms; Prognosismedicine.diseasePrognosisPredictive valuePACCCarboplatinhumanitiesFirst line treatmentovarian cancer030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisFemalebusinessOvarian cancerPredictive factorsResearch PaperpACC
researchProduct

Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas

2017

Advanced soft tissue sarcomas are aggressive cancers with limited therapeutic options. Recently, inhibition of platelet-derived growth factor receptor (PDGFR)-α by the monoclonal antibody olaratumab showed promising clinical activity. If confirmed, this would be one of the first examples of targeted therapy effective in advanced soft tissue sarcomas therapy independently of the histologic subtype. Here, we reviewed the biology of the PDGF/PDGFR axis, particularly focusing on its role in cancer, and then we discussed on the effects of PDGFR-α inhibition in the therapy of advanced soft tissue sarcomas.

0301 basic medicinemedicine.medical_specialtyPathologyReceptor Platelet-Derived Growth Factor alphamedicine.medical_treatmentPDGFR-αAntineoplastic AgentsTargeted therapy03 medical and health sciences0302 clinical medicineGrowth factor receptorDoxorubicin; Olaratumab; PDGFR-α; Soft tissue sarcomas; Hematology; Oncology; Geriatrics and GerontologyInternal medicinemedicineHumansDoxorubicinOlaratumabSoft tissue sarcomaHematologybiologybusiness.industryAntibodies MonoclonalCancerSoft tissueSarcomaHematologySoft tissue sarcomasmedicine.disease030104 developmental biologyOncologyDoxorubicin030220 oncology & carcinogenesisbiology.proteinGeriatrics and GerontologybusinessPlatelet-derived growth factor receptormedicine.drugOlaratumab
researchProduct

Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle

2017

Background Toxicity of chemotherapy on skeletal muscles and the heart may significantly contribute to cancer cachexia, mortality, and decreased quality of life. Doxorubicin (DOX) is an effective cytostatic agent, which unfortunately has toxic effects on many healthy tissues. Blocking of activin receptor type IIB (ACVR2B) ligands is an often used strategy to prevent skeletal muscle loss, but its effects on the heart are relatively unknown. Methods The effects of DOX treatment with or without pre-treatment with soluble ACVR2B-Fc (sACVR2B-Fc) were investigated. The mice were randomly assigned into one of the three groups: (1) vehicle (PBS)-treated controls, (2) DOX-treated mice (DOX), and (3) …

0301 basic medicinemedicine.medical_specialtyTransferrin receptorMyostatinCachexia03 medical and health sciences0302 clinical medicineAtrophyPhysiology (medical)Internal medicinemedicineOrthopedics and Sports MedicineDoxorubicinbiologybusiness.industrySkeletal muscleActivin receptormedicine.disease3. Good health030104 developmental biologymedicine.anatomical_structureEndocrinology030220 oncology & carcinogenesisbiology.proteinbusinessACVR2Bmedicine.drugJournal of Cachexia, Sarcopenia and Muscle
researchProduct

Citrus sinensis and Vitis vinifera Protect Cardiomyocytes from Doxorubicin-Induced Oxidative Stress: Evaluation of Onconutraceutical Potential of Veg…

2020

Abstract: The interest towards nutraceuticals able to counteract drug side effects is continuously growing in current chemotherapeutic protocols. In the present study, we demonstrated that smoothies containing mixtures of Citrus sinensis and Vitis vinifera L. cv. Aglianico N, two typical fruits of the Mediterranean diet, possess bioactive polyphenols that protect cardiomyocytes against doxorubicin-induced oxidative stress. The polyphenolic extracts isolated from Citrus sinensis- and Vitis vinifera-based functional smoothies were deeply characterized by Liquid Chromatography-Mass Spectrometry methods. Subsequently, the functional smoothies and relative mixtures were tested to verify their ab…

0301 basic medicineonconutraceuticalPhysiologyClinical BiochemistrycardiotoxicityAnthracyclinemedicine.disease_causeBiochemistryArticle03 medical and health sciences0302 clinical medicineNutraceuticalmedicineoxidative stressDoxorubicinFood scienceVitis viniferaadjuvant therapy; anthracyclines; antioxidants; apoptosis; cardiotoxicity; functional foods; onconutraceutical; oxidative stress; polyphenolsMolecular Biologypolyphenolsfunctional foodsanthracyclinesChemistryFunctional foodlcsh:RM1-950apoptosisApoptosifood and beveragesadjuvant therapyCell Biology030104 developmental biologyantioxidantslcsh:Therapeutics. PharmacologyApoptosisPolyphenol030220 oncology & carcinogenesisOxidative streBreast cancer cellsAntioxidantCitrus × sinensisOxidative stressmedicine.drugAntioxidants
researchProduct

Synthesis and cytotoxic activity of new artemisinin hybrid molecules against human leukemia cells

2017

A series of new artemisinin-derived hybrids which incorporate cholic acid moieties have been synthesized and evaluated for their antileukemic activity against sensitive CCRF-CEM and multidrug-resistant CEM/ADR5000 cells. The new hybrids 20-28 showed IC50 values in the range of 0.019µM-0.192µM against CCRF-CEM cells and between 0.345µM and 7.159µM against CEM/ADR5000 cells. Amide hybrid 25 proved the most active compound against both CCRF-CEM and CEM/ADR5000 cells with IC50 value of 0.019±0.001µM and 0.345±0.031µM, respectively. A relatively low cross resistance to hybrids 20-28 in the range of 5.7-fold to 46.1-fold was measured. CEM/ADR5000 cells showed higher resistance than CCRF-CEM to al…

0301 basic medicinevirusesClinical BiochemistryPharmaceutical ScienceAntineoplastic AgentsBiochemistryAntileukemic agentStructure-Activity Relationship03 medical and health scienceschemistry.chemical_compound0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesAmideDrug DiscoveryTumor Cells CulturedmedicineHumansCytotoxic T cellDoxorubicinArtemisininMolecular BiologyIC50Cross-resistanceCell ProliferationLeukemiaDose-Response Relationship DrugMolecular StructureOrganic ChemistryCholic acidhemic and immune systemsArtemisinins030104 developmental biologyBiochemistrychemistry030220 oncology & carcinogenesisMolecular MedicineDrug Screening Assays Antitumormedicine.drugBioorganic & Medicinal Chemistry
researchProduct

Identificación de TRIM29 localizado en la región cromosómica 11q23.3 como biomarcador de resistencia a Doxorubicina y proliferación celular en cáncer…

2018

El cáncer de mama es una enfermedad compleja y heterogénea en la que los pacientes pueden presentar síntomas similares y padecer la misma enfermedad por razones genéticas completamente diferentes. Los factores que contribuyen a esta heterogeneidad incluyen la variación en el genoma de cada paciente, las diferencias en el origen y la naturaleza de la célula tumoral y los eventos genéticos que contribuyen a la progresión del tumor. La recaída en cáncer de mama es una de las mayores causas de morbilidad en pacientes que desarrollan la enfermedad y, entre ellas, entre un 15-20% poseerán tumores de mama triple negativo (TN). La mortalidad de pacientes con cáncer de mama TN es considerablemente m…

:CIENCIAS DE LA VIDA::Bioquímica [UNESCO]:CIENCIAS DE LA VIDA::Genética [UNESCO]DOXORUBICINATRIM29AMPLIFICACIÓNUNESCO::CIENCIAS DE LA VIDA::BioquímicaUNESCO::CIENCIAS DE LA VIDA::Biología celularPROLIFERACIÓNDELECIÓNUNESCO::CIENCIAS DE LA VIDA::Genética:CIENCIAS DE LA VIDA::Biología celular [UNESCO]CÁNCER DE MAMATRIPLE NEGATIVO
researchProduct